SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending following its third-quarter earnings report, where strong growth in AI semiconductor revenue—fueled by demand from major hyperscalers—initially drove a volatility-filled trading session. While investors reacted to fourth-quarter revenue guidance that fell slightly short of some high-end estimates, the conversation shifted to optimism after management provided a robust long-term outlook for fiscal 2027 and 2028.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake shares surged significantly after the company reported strong fiscal second-quarter financial results, highlighted by an earnings beat and an upward revision to its full-year product revenue outlook. The community reaction is sharply divided between bulls celebrating the accelerated AI-driven consumption of the company's data cloud tools and bears arguing that the stock's valuation is detached from its continued GAAP losses.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as the community reacts to the upcoming presentation of new preclinical data for the drug SLS009 in pancreatic cancer at a major oncology conference. Investors remain focused on the potential of SLS009 alongside the ongoing Phase 3 trial for Galinpepimut-S, with discussions highlighting high conviction in the clinical pipeline despite ongoing volatility and debate regarding trial timelines.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell shares are trending following a strong quarterly earnings report that featured a significant upward revision to annual revenue guidance and a record AI server backlog, prompting a flurry of analyst price target hikes. While the community is overwhelmingly bullish on the AI infrastructure demand, many traders are actively debating the stock's high volatility and suspecting market manipulation due to rapid intraday price swings.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

Hewlett Packard Enterprise shares are receiving attention following a blowout fiscal third-quarter earnings report that saw the company beat analyst expectations for both revenue and earnings while raising its outlook. While the stock initially fell due to concerns regarding margin pressure and supply-chain constraints, many traders remain bullish, citing record revenue and strong demand in the AI infrastructure sector as long-term catalysts.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending amid ongoing market volatility and sector-wide weakness in data center stocks, with investors weighing the company's long-term growth potential and infrastructure expansion against concerns regarding high capital expenditures and macroeconomic pressures. While some traders express frustration with the recent share price decline and lack of immediate catalysts, others emphasize the company's strong contracted backlog and long-term business fundamentals as reasons to maintain a bullish outlook.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx is trending following the failure of its Phase 3 Aspire study for apazunersen in Angelman syndrome to meet primary and secondary endpoints. The community reaction is sharply divided, with some investors focusing on the significant drop in market capitalization and potential for further downside, while others view the sell-off as an overreaction that creates a buying opportunity ahead of upcoming regulatory catalysts for the company's remaining gene therapy pipeline.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology shares are experiencing significant volatility following a fiscal first-quarter earnings report that featured revenue growth and guidance beats but raised concerns among investors regarding margin compression, operating expenses, and customer concentration. While some traders view the resulting sell-off as an overreaction and a buying opportunity, others remain cautious, pointing to the company's valuation and broader macroeconomic pressures.

Fervo Energy Co. operates as a energy company. It builds and operates power facilities in extracting geothermal energy. The company was founded by Jack Norbeck and Timothy Latimer in 2017 and is headquartered in Berkeley, CA.

Fervo Energy Co. - Ordinary Shares - Class A

Fervo Energy Co

Fervo Energy is attracting significant attention following the announcement of a large power purchase agreement with Google to supply geothermal energy for potential data centers. While some traders view the deal as a major validation of the company's commercial scale and growth potential, others express skepticism regarding the company's profitability, high valuation, and reliance on future project developments.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Phoenix, AZ.

First Solar Inc

First Solar is experiencing downward price pressure and heightened volatility as traders weigh strong quarterly earnings and growth prospects against ongoing concerns regarding tariff policy uncertainty and general weakness in the solar sector. Community sentiment remains split between long-term investors viewing the stock as undervalued for its role in data center energy infrastructure and short-term traders reacting to technical sell-offs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update

BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, Aug. 31, 2026 - Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third...

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement PR Newswire TEL AVIV, Israel, Aug. 28, 2026 TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd...

BioLineRx to Report Second Quarter 2026 Results on August 31, 2026

BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 PR Newswire TEL AVIV, Israel, Aug. 25, 2026 Management to Hold Conference Call at 8:30 a.m. EDTTEL AVIV, Israel, Aug. 25, 2026 /PRNewswire/ -- BioLineRx Ltd...

BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026

BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO...

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and...

BioLineRx (BLRX) Q1 2026 Earnings Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, May 27, 2026 - Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of...

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting PR Newswire TEL AVIV, Israel and OSLO...

BioLineRx to Report First Quarter 2026 Results on May 27, 2026

BioLineRx to Report First Quarter 2026 Results on May 27, 2026 BioLineRx to Report First Quarter 2026 Results on May 27, 2026 PR Newswire TEL AVIV, Israel, May 20, 2026 Management to Hold Conference Call at 8:30 a.m. EDTTEL AVIV, Israel, May 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX...

BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models

BioLineRx shares new GLIX1 glioblastoma data showing anti-tumor activity, including in temozolomide-resistant cancer models.read more...

$BLRX Q2 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.00
• Reported revenue of $0.29M down -3.33% YoY
• BioLineRx is maintaining its cash runway guidance into the first half of 2027, supported by $13.1M in cash, cash equivalents, and short-term bank deposits as of June 30, 2026.

Stocktwits

BioLineRx, Ltd.

 Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.00
• Reported revenue of $0.29M down -3.33% YoY
• BioLineRx is maintaining its cash runway guidance into the first half of 2027, supported by $13.1M in cash, cash equivalents, and short-term bank deposits as of June 30, 2026.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of $0.00
• Reported revenue of $0.29M down -3.33% YoY
• BioLineRx is maintaining its cash runway guidance into the first half of 2027, supported by $13.1M in cash, cash equivalents, and short-term bank deposits as of June 30, 2026.

BioLineRx reported an increased net loss of $4.3M, rising research and administrative operating expenses, ongoing dilution from a $3.75M offering, and regional operational uncertainties stemming from the security situation in Israel.

BioLineRx advanced GLIX1 Phase 1/2a glioblastoma clinical dosing, demonstrated preclinical synergy in ovarian cancer to enable trial expansion and collaboration discussions, while maintaining cash runway guidance into the first half of 2027.

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Feed

News

Sentiment

Earnings

Fundamentals

Info

BLRX BioLineRx, Ltd.

Fundamentals

Latest BLRX News